Brian W. Corrigan
Research Subjects
Brian W. Corrigan has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Allen E. Moton
Early Clinical Research & Experimental Medicine, Schering‐Plough Research Institute, Kenilworth, NJ and
1 shared publicationDaniel Polhamus
Metrum Research Group
1 shared publicationDaniele Ouellet
Clinical Pharmacology, Modeling and Simulation, GlaxoSmithKline, Research Triangle Park, NC
1 shared publicationDiane Stephenson
Critical Path Institute
1 shared publicationDouglas E. Feltner
Department of Neuroscience, Pfizer Global Research and Development, Groton and CQIM and Neuroscience Development, Pfizer Global Research and Development, New London, CT
1 shared publicationGordon Gibson
Neurology and Sleep Medicine, Clinical Study Centers LLC, Little Rock, AR, USA
1 shared publication
Latest Publications
- 11 April 2022
- Published by Springer Nature in Pharmaceutical Research
- Vol. 39 (8) , 1803-1815
Role of Disease Progression Models in Drug Development
The use of Disease progression models (DPMs) in Drug Development has been widely adopted across therapeutic areas as a method for integrating previously obtained disease knowledge to elucidate the impact of novel therapeutics or vaccines on disease course, thus quantifying the potential clinical benefit at different stages of drug development programs. This paper provides a brief overview of DPMs and the evolution in data types, analytic methods, and applications that have occurred in their use by Quantitive Clinical Pharmacologists. It also provides examples of how these models have informed decisions and clinical trial design across several therapeutic areas and at various stages of development. It briefly describes potential new applications of DPMs utilizing emerging data sources, and utilizing new analytic techniques, and discuss new challenges faced such as requiring description of multiple endpoints, rapid model development, application of machine learning-based analytics, and use of high dimensional and real-world data. Considerations for the continued evolution future of DPMs to serve as community-maintained expert systems are also provided.
- 11 April 2022
- Published by Springer Nature in Pharmaceutical Research
- Vol. 39 (8) , 1803-1815
Role of Disease Progression Models in Drug Development
The use of Disease progression models (DPMs) in Drug Development has been widely adopted across therapeutic areas as a method for integrating previously obtained disease knowledge to elucidate the impact of novel therapeutics or vaccines on disease course, thus quantifying the potential clinical benefit at different stages of drug development programs. This paper provides a brief overview of DPMs and the evolution in data types, analytic methods, and applications that have occurred in their use by Quantitive Clinical Pharmacologists. It also provides examples of how these models have informed decisions and clinical trial design across several therapeutic areas and at various stages of development. It briefly describes potential new applications of DPMs utilizing emerging data sources, and utilizing new analytic techniques, and discuss new challenges faced such as requiring description of multiple endpoints, rapid model development, application of machine learning-based analytics, and use of high dimensional and real-world data. Considerations for the continued evolution future of DPMs to serve as community-maintained expert systems are also provided.
- 15 February 2020
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 107 (4) , 697-699
Artificial Intelligence and Machine Learning: Will Clinical Pharmacologists Be Needed in the Next Decade? The John Henry Question
- 15 February 2020
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 107 (4) , 697-699
Artificial Intelligence and Machine Learning: Will Clinical Pharmacologists Be Needed in the Next Decade? The John Henry Question
- 21 July 2012
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 39 (5) , 479-498
Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis
Our objective was to develop a beta regression (BR) model to describe the longitudinal progression of the 11 item Alzheimer’s disease (AD) assessment scale cognitive subscale (ADAS-cog) in AD patients in both natural history and randomized clinical trial settings, utilizing both individual patient and summary level literature data. Patient data from the coalition against major diseases database (3,223 patients), the Alzheimer’s disease neruroimaging initiative study database (186 patients), and summary data from 73 literature references (representing 17,235 patients) were fit to a BR drug-disease-trial model. Treatment effects for currently available acetyl cholinesterase inhibitors, longitudinal changes in disease severity, dropout rate, placebo effect, and factors influencing these parameters were estimated in the model. Based on predictive checks and external validation, an adequate BR meta-analysis model for ADAS-cog using both summary-level and patient-level data was developed. Baseline ADAS-cog was estimated from baseline MMSE score. Disease progression was dependent on time, ApoE4 status, age, and gender. Study drop out was a function of time, baseline age, and baseline MMSE. The use of the BR constrained simulations to the 0–70 range of the ADAS-cog, even when residuals were incorporated. The model allows for simultaneous fitting of summary and patient level data, allowing for integration of all information available. A further advantage of the BR model is that it constrains values to the range of the original instrument for simulation purposes, in contrast to methodologies that provide appropriate constraints only for conditional expectations.
- 21 July 2012
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 39 (5) , 479-498
Combining patient-level and summary-level data for Alzheimer’s disease modeling and simulation: a beta regression meta-analysis
Our objective was to develop a beta regression (BR) model to describe the longitudinal progression of the 11 item Alzheimer’s disease (AD) assessment scale cognitive subscale (ADAS-cog) in AD patients in both natural history and randomized clinical trial settings, utilizing both individual patient and summary level literature data. Patient data from the coalition against major diseases database (3,223 patients), the Alzheimer’s disease neruroimaging initiative study database (186 patients), and summary data from 73 literature references (representing 17,235 patients) were fit to a BR drug-disease-trial model. Treatment effects for currently available acetyl cholinesterase inhibitors, longitudinal changes in disease severity, dropout rate, placebo effect, and factors influencing these parameters were estimated in the model. Based on predictive checks and external validation, an adequate BR meta-analysis model for ADAS-cog using both summary-level and patient-level data was developed. Baseline ADAS-cog was estimated from baseline MMSE score. Disease progression was dependent on time, ApoE4 status, age, and gender. Study drop out was a function of time, baseline age, and baseline MMSE. The use of the BR constrained simulations to the 0–70 range of the ADAS-cog, even when residuals were incorporated. The model allows for simultaneous fitting of summary and patient level data, allowing for integration of all information available. A further advantage of the BR model is that it constrains values to the range of the original instrument for simulation purposes, in contrast to methodologies that provide appropriate constraints only for conditional expectations.
- Open Access
- 7 August 2009
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 68 (2) , 174-180
Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit
- 7 August 2009
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 68 (2) , 174-180
Open AccessEffect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit